ctDNA Shows Promise for Risk Stratification but Mixed Results for Treatment Selection

◇ RESEARCH

A review of circulating tumor DNA in GI cancers found that while postoperative ctDNA positivity identifies high-risk patients, recent trials show mixed results: DYNAMIC-III showed escalation in ctDNA-positive stage III disease did not improve outcomes. (EClinicalMedicine)